ライフサイエンスコーパス: antibody fragment

1 ation rates of T cells independent of the Fc antibody fragment.

2 y a nonionic detergent and complexed with an antibody fragment.

3 compared with mGluR1 IgG fused to a control antibody fragment.

4 agonist BU72 and a G protein mimetic camelid antibody fragment.

5 ceptor site has been shown to be accessed by antibody fragments.

6 fragments, CD4 mimetic proteins, and various antibody fragments.

7 e for the observed dual specificity of these antibody fragments.

8 echanisms, in general, and for single-domain antibody fragments.

9 o production of antigen for pre-selection of antibody fragments.

10 rimarily single copy (monovalent) display of antibody fragments.

11 n seems most favorable for the expression of antibody fragments.

12 ify putative allosteric sites in a series of antibody fragments.

13 and full-length antibody, as well as smaller antibody fragments.

14 The anti-DNA antibody fragment 3E10 Fv has received attention as a no

15 DS6 were used to determine the extent of the antibody fragment (64)Cu-DOTA-B-Fab binding specificity.

16 The antibody fragment (64)Cu-DOTA-B-Fab was more than 95% st

17 monoclonal Fv fragments (3.9 A) and without antibody fragments (8 A).

18 he tumor targeting of an internalizing human antibody fragment, a small-size platform, to provide hig

19 Instead, the binding of the antibody fragment achieves its effect by restoring the s

20 noparticles to 'shuttle' a model therapeutic antibody fragment across the epithelial cell layers.

21 contrast to directly labeled antibodies and antibody fragments, administration of the negatively cha

22 pproach can find utility when an antibody or antibody fragment against a known cell line needs to be

23 ive-cell microscopic imaging of single-chain antibody fragments against carcinoembryonic antigen in L

24 Using monoclonal antibody fragments against nonstructural protein dengue

25 We further demonstrated that single-chain antibody fragments against tumor-specific antigens can b

26 Selected antibody fragments allowed specific detection of endogen

27 Whereas directly conjugated antibodies, fragments and subfragments have shown promis

28 l, we developed a modular system in which an antibody fragment and a cytokine are conjugated via a DN

29 electrode array was functionalised with the antibody fragment and integrated with microfluidics and

30 static attraction can be enhanced between an antibody fragment and its cognate antigen through applic

31 notoxin B3(dsFv)-PE38 (B3-PE38) in which the antibody fragment and the protein toxin are polyionic li

32 ed for efficient production of BsAb, both as antibody fragments and as full-length IgG-like molecules

33 compensates for the rapid blood clearance of antibody fragments and could make the antibody less immu

34 eful in predicting the binding of monovalent antibody fragments and engineered antibody constructs an

35 neering the variable and constant regions of antibody fragments and full-length antibodies to resist

36 antibodies, are the smallest antigen-binding antibody fragments and have ideal characteristics for PE

37 ntial reassembly of fusion proteins based on antibody fragments and interleukin-12 subunit mutants.

38 pproach to PEGylation of cytokines, enzymes, antibody fragments and peptides, without destroying thei

39 t of FR104 (n=5), a selective pegylated Fab' antibody fragment antagonist of CD28 that does not block

40 A single-chain antibody fragment (anti-1F12 scFv) was isolated that rec

41 e antibody single-chain Fv fragments (scFv), antibody fragment-antigen binding (Fab') units, and apta

42 of the 5F7 anti-HER2 Nanobody (single-domain antibody fragment; approximately 13 kDa) after (18)F lab

43 Bispecific antibodies and antibody fragments are a new class of therapeutics incre

44 Here, antibody fragments are constructed to target murine CD8

45 ry was generated in which multiple copies of antibody fragments are displayed on each phage.

46 Antibody fragments are emerging as promising biopharmace

47 Antibody fragments are recognized as promising vehicles

48 molecules, in which anti-CD19 and anti-CD22 antibody fragments are site-specifically modified with F

49 mely single-chain Fv and heterodimeric F(AB) antibody fragments, are export-competent only in strains

50 unique IDE conformation by using a synthetic antibody fragment as a crystallization chaperone.

51 on and site-specifically labeled recombinant antibody fragments as binders to improve the assay perfo

52 e unique properties of camelid single-domain antibody fragments as structural probes for studying the

53 icase domain in complex with DNA and with an antibody fragment, as well as SAXS and domain associatio

54 K+ channel in complex with a monoclonal Fab antibody fragment at 2.0 A resolution.

55 hybrid sensor consists of anti-TNT specific antibody fragments attached to a hydrophilic QD via meta

56 ET-MALDI-MS detection, a proof of concept of antibody fragment background reduction in the ISET-MALDI

57 uctured nature, specific recognition with an antibody fragment becomes feasible and may help define t

58 thod required additional purification of the antibody fragments before immobilization.

59 ith the TNB recognition element bound in the antibody fragment binding site, bringing the two dyes in

60 We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse mode

61 a panel of chimeric rabbit/human monoclonal antibody fragments (both Fab and scFv) against rHBeAg.

62 g peptide and another using a fusion with an antibody fragment, both targeting the erythrocyte-specif

63 o offer a new generation of in vitro-derived antibody fragments, both for further engineering as dire

64 te in size between peptides and single chain antibody fragments, both of which are superior to antibo

65 n of model analyte cardiac troponin I by two antibody fragments brought the label moieties together a

66 ful detection of antigen with a spin labeled antibody fragment by continuous-wave electron paramagnet

67 protein, which were selectively cleaved into antibody fragments by 2-mercaptoethylamine.

68 The recombinant antibody light chain antibody fragment, c23.5, showed alpha-secretase-like ac

69 ow, in addition, that the binding of a camel antibody fragment, cAb-HuL6, which was raised against wi

70 the efficacy of a llama-derived, heavy-chain antibody fragment called anti-rotavirus protein (ARP1),

71 tisense molecules, aptamers, antibodies, and antibody fragments, can be aimed at molecular targets.

72 s that contain disulfide bonds, such as scFv antibody fragments, can be translocated via Tat only whe

73 Infusion of these radiolabeled antibody fragments, combined with SPECT, produces clear

74 tide antigen fused to an erythrocyte-binding antibody fragment completely prevented diabetes onset in

75 report the structures of four AAV-monoclonal antibody fragment complexes, AAV1-ADK1a, AAV1-ADK1b, AAV

76 Therefore, pre-conditioning cells to express antibody fragments confers effective intracellular immun

77 ring cost of bacterially expressed PEGylated antibody fragments could provide decisive advantages for

78 Next, EETI 2.5F was fused to an antibody fragment crystallizable (Fc) domain (EETI 2.5F-

79 d trajectories of two proteins (lysozyme and antibody fragment D1.3) in 4 M glycerol to rigorous stat

80 The results show the importance of antibody fragment density on nanoparticle uptake, and su

81 r a monoclonal antibody and its single-chain antibody fragments derivatives.

82 Three antibody fragments derived from huDS6 were produced, pur

83 d by the development of robust high affinity antibody fragments derived from the breast cancer therap

84 San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, th

85 (99m)Tc-cAbVCAM1-5, a single-domain antibody fragment directed against mouse or human vascul

86 as also tested using a single-chain variable antibody fragment directed against the FVIII light chain

87 ic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surfac

88 utralizing Nanobodies (single domain camelid antibodies fragment) directed against several chemokines

89 Genetically engineered antibody fragments display rapid, high-level tumor uptak

90 Additionally, the highest-affinity antibody fragment displayed 10-fold-increased broad neut

91 ace plasmon resonance-based immunoassay, the antibody fragment displayed cross-reactivity with seven

92 stems include the selection and evolution of antibody fragments, DNA binding domains, enzymes, intera

93 sized that the smallest independently folded antibody fragments (domains) could exhibit exceptionally

94 show, there is tremendous potential for all antibody fragments either as robust diagnostic reagents

95 Here we show that antibody fragments engineered to recognize the protectiv

96 rate that the topically applied single-chain antibody fragment ESBA105 penetrated into the anterior c

97 Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and

98 ion was used for the selection of mutant Fab antibody fragments exhibiting improved expression in the

99 The SPR partition data obtained for the antibody fragment F63, the HIV fusion inhibitor enfuvirt

100 An antibody fragment (Fab) of MAb E was found to neutralize

101 d the energetics of binding of a therapeutic antibody fragment (Fab) to the native and non-native for

102 opy to correlate the number of antibodies or antibody fragments (Fab) bound to an individual virion w

103 In this work, we adopt a methodology using antibody fragments (Fab) conjugated to gold nanoparticle

104 experiments between a set of nine monoclonal antibody fragments (Fab) directed to defined epitopes th

105 kungunya virus-like particles complexed with antibody fragments (Fab) of two highly protective human

106 a broad spectrum of neutralizing monoclonal antibody fragments (Fab).

107 y fragments (for example, classic monovalent antibody fragments (Fab, scFv)) and engineered variants

108 We constructed a synthetic antibody-fragment (Fab) library in the phage-display for

109 pe variants (IgG1, IgG2, IgG3, and IgG4) and antibody fragments [Fab, F(ab')(2)] were expressed in Ch

110 used a conformationally selective synthetic antibody fragment (Fab30) that recognizes the phosphopep

111 structure of natural BfAChE in complex with antibody fragment Fab410.

112 Crystal structures of antibody fragments (Fabs) 311 and 317 with an (NPNA)3 pe

113 Here we identified a series of synthetic antibody fragments (Fabs) against different conformation

114 Antibody derivatives, such as antibody fragments (Fabs) and single-chain variable frag

115 Here we describe synthetic antibody fragments (Fabs) as structural and biochemical

116 -diversity phage display library to engineer antibody fragments (Fabs) that can modulate the activity

117 By using rational design, antibody fragments (Fabs) that mimic thrombopoietin (TPO

118 Radiolabeling of antibodies and antibody fragments facilitates the development of new ta

119 ispecific antibodies in which a BBB-crossing antibody fragment FC5 was used as a BBB carrier.

120 wo chimeric human-mouse recombinant anti-PrP antibody fragments followed by an anti-human IgG seconda

121 Examining the half antibody fragments for detection of the pathogen in the

122 uction of other disease-targeting bispecific antibody fragments for early detection and diagnosis of

123 We screened 12 proteolytic recombinant antibody fragments for potential alpha-secretase activit

124 versatile platform for generating bispecific antibody fragments for redirected killing and, with the

125 acle is to tether cytokines to antibodies or antibody fragments for targeted cell delivery.

126 Smaller recombinant antibody fragments (for example, classic monovalent anti

127 ) and feline parvovirus (FPV) complexed with antibody fragments from eight different neutralizing mon

128 xpression of an anti-digoxin single-chain Fv antibody fragment fused to the C terminus of ClyA result

129 levels of recombinant VHH or single-chain Fv antibody fragments fused to the human immunoglobulin G1-

130 ing and immunofluorescence, can be used with antibody fragments generated by display technologies.

131 y purified immunoglobulin, or papain-cleaved antibody fragments had no effect on growth.

132 The crystal structure of LMO2 with this antibody fragment has been solved revealing a conformati

133 Monoclonal antibodies (mAbs) and antibody fragments have become an emerging class of ther

134 Engineered antibody fragments have been developed with the appropri

135 Antibody fragments have been forged into multivalent and

136 These antibody fragments have great potential for diagnosis an

137 Antigranulocyte antibodies and antibody fragments have limitations and are not widely a

138 The second light chain antibody fragment, hk14, demonstrated carboxypeptidase-l

139 ts include the approved humanized monoclonal antibody fragment idarucizumab for reversing the effects

140 lysine epitopes or the human single-chain Fv antibody fragment IK17 targeted to MDA-like epitopes ("t

141 mphipathic helix that makes contact with the antibody fragment in such a way that the hydrophobic fac

142 old more sensitive detection of human Vkappa antibody fragments in ELISA.

143 The current trend of using recombinant antibody fragments in research to develop novel antidote

144 published methods, we assembled two parental antibody fragments in the hinge region by the protein tr

145 of anti-interleukin (IL)-17A and anti-IL-13 antibody fragments in the lungs and to improve their the

146 that affect the residence time of PEGylated antibody fragments in the lungs following pulmonary deli

147 ants in complexes with conformation-specific antibody fragments in the outward-open and inward-open s

148 IAC facilitates the capture of antibody fragments, in this case single-chain Fvs (scFvs

149 Monoclonal antibody fragments included Fab' fragments derived from

150 In this study, small and bivalent antibody fragments, including anti-prostate-specific mem

151 By assembling and testing several anti-CD20 antibody fragment-interferon ?

152 The antibody fragment is a tool for dissecting LMO2 function

153 in we describe a novel approach in which the antibody fragment is tagged with two handles: one for th

154 nt activation) to a cell surface by means of antibody fragments is feasible and that cell-targeted DA

155 or stabilized by a G-protein mimetic camelid antibody fragment isolated by conformational selection u

156 etection of a chemical flame retardant using antibody fragments isolated from an alpaca has been deve

157 cal characterization of an oligomer-specific antibody fragment, KW1.

158 Antibodies, and engineered antibody fragments, labeled with radioisotopes are being

159 r, compared with full-size antibodies, these antibody fragments lack the ability to bind the neonatal

160 of allergen-specific IgE with combinatorial antibody fragment library technology to analyze immunogl

161 ibodies into Fab, scFv or even single-domain antibody fragments like VHHs will be reviewed.

162 used to treat cancer that are composed of an antibody fragment linked to a toxin.

163 The use of these single-domain antibody fragments may greatly facilitate the successful

164 ortantly, our results suggest that PEGylated antibody fragments may represent a unique approach for m

165 These results demonstrate that antibody fragment mediated proteolytic degradation of Ab

166 ies of an iodinated anti-p185HER2 engineered antibody fragment [minibody (scFv-C(H)3)2; 80 kDa], made

167 Here we develop single-chain antibody fragments (nanobodies) against tubulin to achie

168 We generated a camelid antibody fragment (nanobody) to the human beta(2) adrene

169 We show for the first time that half antibody fragments obtained by reduction via tris(2-carb

170 ent regions of the antibody from analysis of antibody fragments obtained from FabRICATOR digestion.

171 es to half-life extenders such as monoclonal antibodies, fragments of antibodies, and albumin.

172 usly been reported that several single-chain antibody fragments of human origin (scFv) neutralize the

173 timing of maximum binding of each anti-PSMA antibody fragment on the cell surface in vivo in mice be

174 led sequential assembly of biotin-engineered antibody fragments on a streptavidin scaffold with a def

175 The expression of recombinant antibody fragments on the surface of mammalian cells has

176 exelizumab (a novel C5 complement monoclonal antibody fragment) on infarct size in patients receiving

177 at the structural differences of immobilized antibodies (fragmented or intact) significantly influenc

178 an azide-modified fluorescent single-domain antibody fragment or an intact immunoglobulin produced i

179 alysis of LRP6(1-4) bound to a noninhibitory antibody fragment or to full-length Dkk1 shows that in b

180 ular, and site-specific methods for coupling antibody fragments or bioactive proteins to nucleic acid

181 e adapted for broader use, for example, with antibody fragments or other binders generated by display

182 PET/SPECT) of cancer with radiometal-labeled antibody fragments or peptides is hampered by low tumor-

183 e applied to accurately predict antibody and antibody fragment penetration distance in tumor tissue.

184 orming quantitative imaging on murine (124)I antibody fragment PET images using a large-bore clinical

185 he smallest fully functional antigen-binding antibody fragments possessing ideal properties as probes

186 argeting vectors for TRT include antibodies, antibody fragments, proteins, peptides, and small molecu

187 V gp120 and its complexes with receptors and antibody fragments provide high-resolution pictures of s

188 (124)I labeling of engineered antibody fragments provides a promising new class of tum

189 s used to deliver a recombinant single-chain antibody fragment rabbit intrabody (pAd-2S03) capable of

190 We employed high-affinity recombinant antibody fragments (recFab) reacting with residues 95-10

191 n which scTRAIL was additionally fused to an antibody fragment recognizing epidermal growth factor re

192 connecting via a flexible peptide linker two antibody fragments recognizing non-overlapping epitopes

193 en-specific monoclonal antibodies (mAbs) and antibody fragments relies on high-throughput screening o

194 he nonpathogenic wild strain showed that the antibody fragments retained their specific antigen bindi

195 The resulting chemically modified antibody fragment, RGD-Man(5)-IgG1 Fc (5), retained biol

196 Cargos in the form of synthetic antibody fragments (sABs) were conjugated to the enginee

197 The 4M5.3 anti-fluorescein single chain antibody fragment (scFv) contains 14 mutations from the

198 ne that expresses a recombinant single-chain antibody fragment (scFv) derived from an NS1-specific mo

199 denovirus (AV1Y28) expressing a single-chain antibody fragment (scFv) directed against Ras proteins r

200 s-driven mathematical model for single-chain antibody fragment (scFv) folding in Saccharomyces cerevi

201 onding conventional ER-targeted single-chain antibody fragment (scFv) intrabodies demonstrated that t

202 of a novel internalizing human single chain antibody fragment (scFv) labeled with ((9)(9)m)Tc (((9)(

203 n consisting of an idiotypic single chain Fv antibody fragment (scFv) linked to a cytokine (GM-CSF) o

204 molecular design of a single chain variable antibody fragment (scFv) that binds with high affinity t

205 ifferentiation 3 (CD3)-specific single-chain antibody fragment (scFv), effectively redirected T cells

206 ed gold cluster (MPC) with a single chain Fv antibody fragment (scFv), mutated to present an exposed

207 A prostate tumor-targeting single-chain antibody fragment (scFv), UA20, along with a nonbinding

208 n particular, smaller, single-chain-variable antibody fragments (scFv's) are attractive for detecting

209 Here we show that single chain antibody fragments (scFv's) isolated from naive phage di

210 tibody fragments, usually as single-chain Fv antibody fragments (scFv), bind their antigens in an int

211 inimal functional unit (i.e., a single-chain antibody fragment [scFv]) is an effective strategy for r

212 ion of an inhibitory anti-ATF-1 single-chain antibody fragment, ScFv, significantly interfered with D

213 sed to a high-affinity anti-fluorescein scFv antibody fragment (scFvFITC).

214 Single-chain antibody fragments (scFvs) are first isolated from an ex

215 es, and we have selected two single-chain Fv antibody fragments (ScFvs) by panning on a prothrombin-c

216 of human-based single chain variable domain antibody fragments (scFvs) directed against the Abeta 25

217 We were able to isolate single chain antibody fragments (scFvs) from a phage displayed antibo

218 11 unique human single-chain variable region antibody fragments (scFvs) that bind the envelope protei

219 composed of a few neutralizing single chain antibody fragments (scFvs) that bind to two different ep

220 arge phage display libraries of single-chain antibody fragments (scFvs), the three-stage approach tha

221 esigning (18)F-labeled camelid single-domain antibody fragments (sdAbs) specifically targeting the ma

222 ovided an insight into understanding how the antibody fragments self-assemble on the QD.

223 nteraction provides a way of controlling the antibody fragment serum half-life without compromising e

224 crystal structure in complex with a camelid antibody fragment show that the doublecortin C-terminal

225 assignments for two distinct, high affinity antibody fragments (single chain variable and antigen-bi

226 A single chain camelid antibody fragment specific for the C-terminal doublecort

227 We evaluated a small engineered antibody fragment specific for the HER2 receptor tyrosin

228 recently found that a CAR composed of a scFv antibody fragment specific for the Tn-glycoform of MUC1

229 Antibody fragments specific for fetal NRBCs were isolate

230 We developed alpaca-derived antibody fragments specific for mouse class II MHC and C

231 ty trade-offs, we have selected single-chain antibody fragments specific for the negatively charged a

232 These findings for diverse antibodies and antibody fragments specific for unrelated antigens sugge

233 mass spectrometry reveal that binding of the antibody fragment strongly inhibits the locally cooperat

234 Site-selectively modified antibody fragments such as the one described here may be

235 Single domain antibody fragments, such as camelid-derived VHHs, can se

236 Engineered antibody fragments, such as diabodies, minibodies, and s

237 Here we show that a single chain antibody fragment (syn-10H scFv) isolated from a phage d

238 In August 2012, ranibizumab, a monoclonal antibody fragment targeting VEGF designed for ocular use

239 ollowing engagement by a bivalent engineered antibody fragment that binds CD37 and activates both SHP

240 Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affini

241 er protein consists of a single chain (scFv) antibody fragment that binds to a fluorescent hapten con

242 blockading RAS-effector interactions with an antibody fragment that binds to activated RAS, and show

243 nding site of Fab2C4, a humanized monoclonal antibody fragment that binds to the extracellular domain

244 mation of this complex using a single domain antibody fragment that inhibits LMO2 by sequestering it

245 he sensor consists of a dye-labeled anti-TNT antibody fragment that interacts with a cofunctional sur

246 ch the tumor cell specificity of a humanized antibody fragment that recognizes CD3 on T cells is chem

247 C precursors was rescued via tethering to an antibody fragment that specifically binds the human RBC

248 ution, we engineered a high-affinity camelid antibody fragment that stabilizes the active state of th

249 By using antibody fragments that are specific to the target biomo

250 use of chemically or genetically engineered antibody fragments that can be attached to the sensor su

251 ew generation of radiolabeled antibodies and antibody fragments that can be used as cancer-specific i

252 imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiome

253 Previously, we identified two light-chain antibody fragments that had proteolytic activity against

254 Intracellular antibody fragments that interfere with molecular interac

255 odies are noncovalent dimers of single-chain antibody fragments that retain the avidity of intact IgG

256 selection strategy for conformation specific antibody fragments that stimulate procaspase activity, s

257 ory assays require the use of antibodies and antibody fragments that strongly bind to their cell surf

258 ary in the phage-display format and isolated antibody-fragments that bind pMHC with high affinity and

259 Anti-fibers as well as anti-PAO antibodies fragment the amyloid fibers, however the frag

260 bitors were sequestered with an anti-digoxin antibody fragment, the sodium excretion rates in the oua

261 ating the size and format of anti-p185(HER2) antibody fragments, the kidney activity was reduced and

262 to the coreceptor-binding region by smaller antibody fragments, the single-domain (VHH) version of J

263 Rabbit anti-RANKL IgG antibody or F(ab') antibody fragments thereof were injected into the palata

264 Here we show that human single-chain antibody fragments (three domain, V(H)/K form) and an en

265 e have isolated an anti-LMO2 single chain Fv antibody fragment to determine if intracellular interfer

266 demonstrate that using a unique GTP-specific antibody fragment to monitor GTPase cycling in the prese

267 The binding of this engineered antibody fragment to the amyloidogenic variants of lysoz

268 f the fragment with a PEG moiety or a second antibody fragment to tune its circulatory half-life or i

269 relative binding capabilities of antibodies/antibody fragments to cell surface targets on the bencht

270 ate the use of luminescent QDs conjugated to antibody fragments to develop solution-phase nanoscale s

271 roperties of synthetic receptor ligands with antibody fragments to develop useful biochemical tools a

272 adiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment,

273 These results support the use of recombinant antibody fragments to inhibit NS3 enzyme as a novel, fea

274 ter, with and without the cocrystallized Fab antibody fragment, to investigate the properties of this

275 ression or folding, only a few antibodies or antibody fragments, usually as single-chain Fv antibody

276 erized a caffeine-specific, heavy-chain-only antibody fragment (V(HH)) from llama that is capable of

277 Camelid-derived single-domain antibody fragments (VHHs or nanobodies) offer a possible

278 ted a panel of camelid-derived single-domain antibody fragments (VHHs) against influenza virus nucleo

279 used (89)Zr-labeled PEGylated single-domain antibody fragments (VHHs) specific for CD8 to track the

280 From a library of heavy chain-only antibody fragments (VHHs), we isolated an antibody (1B7)

281 M can be robustly applied across a series of antibody fragments (VL to Fab), and subsequently, the DC

282 rental clone the resultant affinity-enhanced antibody fragment was applied in an optimized fluorescen

283 The antibody fragment was, however, not stable enough under

284 Idarucizumab, an antibody fragment, was developed to reverse the anticoag

285 Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoag

286 gen-binding activity of a human single-chain antibody fragment were simultaneously improved.

287 Monoclonal antibody fragments were covalently linked to liposomes c

288 Antibody fragments were predominately located within the

289 Three antibody fragments were produced and examined as potenti

290 iple, nanorobots loaded with combinations of antibody fragments were used in two different types of c

291 These carbohydrate-free antibody fragments were used to bind the glycoprotein ho

292 Our study provided a novel monoclonal scFv antibody fragment which specifically bound to HSP60 of S

293 to study a model system consisting of a Fab antibody fragment with specificity toward the peptide ab

294 Radioiodinated antibody and antibody fragments with (125)I were used to determine th

295 ingle domains represent a promising class of antibody fragments with applications as therapeutic moda

296 positive cancer cells, as well as multimeric antibody fragments with enhanced activity.

297 ovide guidelines for designing other grafted antibody fragments with hydrophobic binding loops.

298 logies is expected to include antibodies and antibody fragments with novel mechanisms of action and e

299 Antibody fragments with optimized pharmacokinetic profil

300 inding affinity over those of the individual antibody fragments (with association constants K(A) and